ARTICLE / CLIENT ALERT
UK Supreme Court: Individuals Subject to Criminal Investigation Have Reasonable Expectation of Privacy Until Charge
March 7, 2022
Read time: 9 min
On 16 February 2022, the UK Supreme Court in Bloomberg LP v ZXC [2022] UKSC 5 unanimously upheld the decisions of two lower courts that Bloomberg was wrong to publish an article identifying a US executive who was under investigation in relation to allegations of fraud, bribery and corruption as he had a reasonable expectation of privacy unless and until he was charged.
The court found that Bloomberg misused the executive’s private information when it reported on a confidential letter of request sent by a UK legal enforcement agency to its counterpart in a foreign state.
As a general rule or as a legitimate starting point, a person under criminal investigation has a reasonable expectation of privacy in respect of information relating to that investigation unless and until they are formally charged.
This judgment is significant not only in confirming the reputational protections available to individuals who are the subject of criminal investigation, but also in the development of English privacy law more generally. It shows an appetite by the courts to bolster (at least on an individual basis) the right to privacy in a world where that right is increasingly under challenge.
The executive (a US citizen) and his corporate employer were the subject of a criminal investigation by a UK law enforcement agency. During that investigation, the UK agency sent a confidential letter of request to its counterpart in a foreign state seeking, among other things, information and documents relating to the executive. The letter expressly requested that its existence and contents remain confidential.
Bloomberg obtained a copy of the letter and published an article reporting that information had been requested in relation to the executive and detailing the matters in respect of which he was being investigated. Bloomberg refused to remove the article from its website. Following an unsuccessful application for an interim injunction, the executive brought a claim against Bloomberg under the tort of misuse of private information.
This tort is relatively new to English law, having first been recognised as a distinct cause of action in the early 2000s in supermodel Naomi Campbell’s successful appeal to the House of Lords in her claim against The Mirror newspaper for publishing photos of her leaving a rehabilitation clinic following public denials that she was a recovering drug addict.
The executive succeeded at first instance, again on appeal to the Court of Appeal and also at the Supreme Court, with the Supreme Court confirming that the tort requires a two-stage test:
- First, whether the claimant objectively has a reasonable expectation of privacy in the relevant information considering all the circumstances of the case.
- Second, whether the expectation is outweighed by the publisher’s right to freedom of expression. This involves a balancing exercise between the claimant’s European Convention on Human Rights (ECHR) Article 8 right to privacy and the publisher’s ECHR Article 10 right to freedom of expression.
Bloomberg advanced four arguments challenging the lower courts’ suggestion that there may be a “general rule” or “legitimate starting point” that a person under criminal investigation has, prior to being charged, a reasonable expectation of privacy in respect of information relating to that investigation:
- Bloomberg argued that, because the public knows there to be a presumption of innocence under English law, the application of a general rule or legitimate starting point is unsound because it overstates the extent to which publication would in fact damage an individual’s reputation. The Supreme Court gave this short shrift, noting that it is undeniable that a person’s reputation will ordinarily be adversely affected if they are reported as being the subject of a criminal investigation – regardless of whether they are actually charged – impacting their right to respect for private life.
- Bloomberg submitted that the lower courts were incorrect to rely on the human psychological tendency to presume that there is “no smoke without fire” as this runs contrary to well-established principles in defamation law that the ordinary reasonable reader can distinguish suspicion from guilt. However, the Supreme Court found that the tort of misuse of private information is a separate tort from defamation and, unlike the latter, its purpose is not only to protect an individual from the publication of untrue information, but also to protect their private life (regardless of the truth or falsity of the information).
- Bloomberg argued that information should not be protected on the basis that it is reputationally damaging, but instead on the basis that it belongs to that part of the claimant’s life that is of no one else’s concern. As such, Bloomberg argued that the executive’s business activities should not be protected. The Supreme Court found this unduly restrictive, holding that a person’s business reputation falls within the scope of ECHR Article 8, provided that the attack on reputation is serious enough to prejudice that individual’s right to respect for private life.
- Bloomberg argued that the lower courts failed to apply the correct legal test at stage one, as a consideration of “all the circumstances of the case” should have included the nature of the alleged activity (i.e., fraud, bribery and corruption) and that executives involved in the affairs of large public companies knowingly lay themselves open to close scrutiny by the media. However, the Supreme Court found that the private nature of the information was not affected by the specifics of the activities being investigated and, while the executive’s status might mean that the limits of acceptable criticism are wider than for a private individual, there is still a limit.
Comment
Whilst, as a matter of legal principle, individuals are presumed to be innocent unless proven otherwise, it is widely accepted that an innocent person’s reputation, and therefore their right to respect for private life, can be seriously and permanently damaged by the publication of the fact that they are subject to a criminal investigation. This is why state investigatory bodies generally do not identify those under investigation prior to charge and partly why, in this case, the UK agency asked for the existence and content of the letter to be kept confidential.
This point was made in the Leveson Inquiry Report, has been endorsed by the Government and the Judiciary, and has arisen in a string of cases in the lower courts. In 2016, an independent review into the Metropolitan Police Service’s handling of non-recent sexual offence investigations alleged against persons of public prominence found:
Present arrangements […] have caused the most dreadful unhappiness and distress to numerous suspects, their families, friends and supporters. Those consequences were avoidable by protecting anonymity. Nobody is safe from false accusation and damaging exposure under present arrangements. A reputation built on a lifetime of public service or popular entertainment can be extinguished in an instant.
The judgment against Bloomberg in the present case is therefore important in providing confirmation from the highest court in the land that there does indeed exist a “general rule” of pre-charge anonymity.
While the decision will be unwelcome for the British media (which might argue that the decision prevents journalists from putting the conduct of companies and individuals under appropriate scrutiny), it is a positive development for those under investigation (and, by association, their employers) given the protection it gives to their reputations prior to charge. It is likely that if such individuals are not charged, the fact of their involvement in the investigation may never reach the public eye.
In terms of wider consequences:
- It will be interesting to see whether this judgment lowers the bar for law enforcement officers to include individuals in their investigations, given the reduced likelihood that such individuals’ identities will be revealed prior to charge.
- The question of whether there is a reasonable expectation of privacy is fact-specific and a balancing exercise must be undertaken between the right to privacy and the right to freedom of expression. As a result, in certain cases, it may still be appropriate for the media to publish the identity of individuals under investigation prior to charge. Such circumstances are likely to be rare (the court identified a possible example being where the press alleges inadequacies in the conduct of the investigation). Except in the most obvious cases, the press would therefore be at significant risk of being sued.
- As non-governmental corporates are also able to benefit from the protections under ECHR Article 8, there is perhaps some scope for argument that they too should benefit from pre-charge anonymity, at least until the relevant agency announces that it has opened a formal investigation. However, this argument may struggle at both stage one and stage two of the test, given that there would not normally be a reasonable expectation of privacy in relation to non-confidential corporate information and, even if there were, the balancing exercise for a corporate may well come out on the side of freedom of expression.
- Finally, it is interesting to see this judgment in the context of the evolving landscape of data privacy law in the UK and the increased activism of the courts in cementing such rights. As discussed above, it was the predecessor to the Supreme Court (the House of Lords) that in the early 2000s first distinguished the tort of misuse of private information. This tort, together with the rights accruing to individuals under the General Data Protection Regulation (GDPR) and the investigatory powers of the Information Commissioner’s Office, now provides the bedrock for the enforcement of individuals’ data privacy rights, with significance not only for corporate investigations but also for civil litigation more generally. While the Supreme Court may have reduced the scope for group claims in the UK for breach of data privacy laws in its recent decision in Lloyd v Google [2021] UKSC 50 (given that the need to bifurcate proceedings between liability and damages makes such cases unsuitable for litigation funding), it nevertheless found that the tort of misuse of private information would likely have been available for claims brought on an individual basis and expressly did not comment on whether such claims could be brought under the GDPR.

Utah Poised to Enact Consumer Privacy Law
ARTICLE / CLIENT ALERT
Utah Poised to Enact Consumer Privacy Law
March 4, 2022
Read time: 4 min
On March 3, 2022, the Utah House of Representatives unanimously passed a consumer privacy bill which the Utah Senate passed earlier this year. The bill, entitled the Utah Consumer Privacy Act, still has several hurdles to jump through before becoming law. Leaders from both legislative chambers will need to provide their signatures before the 2022 session adjournment on March 4, 2022; following those signatures, Utah Governor Spencer J. Cox has 20 days to sign or veto the bill before it becomes law. Despite these remaining hurdles, the bill is widely expected to become the fourth comprehensive state consumer privacy law in the United States and the first such bill to become law in 2022.

The Utah Consumer Privacy Act would apply to businesses who:
- Conduct business in Utah or produce a product or service targeted to Utah residents;
- Have an annual gross revenue of over $25 million; and
- Either (i) control or process the personal data of at least 100,000 residents or (ii) derive over 50% of its gross revenue from the “sale” of personal data and controls or processes personal data of at least 25,000 residents.
The Act’s applicability would make it narrower than any currently enacted state privacy law to date. And as with other state laws, the Act contains broad exceptions for certain entities and data categories, including higher education institutions, nonprofits, and information and entities regulated by both the Health Insurance Portability and Accountability Act (HIPAA) and the Gramm-Leach-Bliley Act (GLBA).
The Act, which is scheduled to take effect on December 31, 2023, includes many of the same rights, obligations and exceptions that have become common in other consumer privacy laws and proposals:
- The Act provides consumers with the now well-known rights of notice, access, portability and deletion. These rights, however, are limited by reasonable business-use exemptions, such as detecting fraud and complying with a company’s legal obligations. Notably, the Act does not provide consumers with the right to correction.
- Like other laws, the Utah Consumer Privacy Act allows consumers to opt-out of the use of their information for certain purposes, including targeted advertising and the sale of personal information. Unlike other state laws, the Utah Consumer Privacy Act does not allow consumers to opt-out of automated “profiling.”
- The “personal information” protected by the bill includes information that is linked or reasonably linkable to an identified or identifiable individual. “Personal information” does not include deidentified, aggregated or publicly available information.
- The Act would exclude employee data and business-to-business contact information from its scope, following similar exclusions in other states.
- The Act creates a category of “sensitive” information, which includes information about racial or ethnic origin, religious beliefs, sexual orientation, citizenship or immigration status, health, biometric or genetic data, and geolocation data. However, instead of following the Virginia/Colorado model and requiring opt-in consent for the collection and processing of sensitive information, the Act would require businesses to provide notice and an opportunity to opt out of the use of “sensitive” data.
- The Utah Consumer Privacy Act is exclusively enforced through actions by the Utah Attorney General. The law does not provide for a private right of action.
- The Act grants the Utah Department of Commerce Division of Consumer Protection the power to investigate consumer complaints regarding the processing of their personal information by a business. If the director of the Division of Consumer Protection has reasonable cause to believe that substantial evidence exists that the business is in violation of the law, the director will then refer the matter to the Attorney General.
Our Global Data Privacy and Cybersecurity team can help you assess the applicability of this new law and work with companies to ensure compliance. For assistance, please contact either Amy Pimentel or David Saunders.

Ukraine Crisis: UK Government Imposes Significant Sanctions Against Russia
ARTICLE / CLIENT ALERT
Ukraine Crisis: UK Government Imposes Significant Sanctions Against Russia
March 3, 2022
Read time: 7 min
The United Kingdom (UK) is imposing new sanctions on Russia almost daily in response to the ongoing and deteriorating situation in Ukraine. The newest measures include asset freezes, economic prohibitions, and other trade and financial restrictions. In this On the Subject, our trade and sanctions team provides an update on the latest sanctions since our previous alert as well as an overview on the impact of these sanctions on businesses.
TIMELINE OF UK FINANCIAL AND ECONOMIC RESTRICTIONS AGAINST RUSSIA
The Russia (Sanctions) (EU Exit) Regulations 2019 (2019 Regulations) is the key legal act setting out UK sanctions against Russia (as retained under UK law following Brexit). Although the 2019 Regulations originate from European law, there has been significant divergence between the scope of UK and European Union (EU) sanctions. As of 3 March 2022, there have been five amendments to the 2019 Regulations in response to Russia’s actions. These amendments expand the scope of the existing restrictions and impose new ones. They are as follows:
- The Russia (Sanctions) (EU Exit) (Amendment) Regulations 2022 (10 February 2022) amend the designation criteria under Regulation 6 of the 2019 Regulations to specify additional activities for which a person may be designated. Under the amended criteria, an “involved person” now includes a person who is or has been involved in “obtaining a benefit from or supporting the Government of Russia“. The amendment also defines sectors of strategic significance to the Russian government as the chemicals, construction, defence, electronics, energy, extractives, financial services, information, communications, and digital technologies and transport sectors.
- The Russia (Sanctions) (EU Exit) (Amendment) (No. 2) Regulations 2022 (1 March 2022) amend the 2019 Regulations to impose significant new financial restrictions, including:
- A prohibition on dealing with transferable securities and money market instruments issued on or after 1 March 2022 by the following:
- An entity incorporated or constituted under UK law and owned by an entity listed in Schedule 2, or an entity acting on behalf of or at the direction of such an entity, where the security/instrument has a maturity exceeding 30 days;
- A “person connected with Russia” (subject to certain exceptions) or an entity owned by or acting on behalf/at the direction of a “person connected with Russia”; or
- The Russian government.
- Amendment and expansion of the scope of existing prohibitions on issuing loans or credit to include loans or credit made or granted to the following:
- An entity incorporated or constituted under UK law and owned by an entity listed in Schedule 2;
- An entity “connected with Russia” or owned or acting on behalf of, or at the direction of a person “connected with Russia”; or
- The Russian government.
- A prohibition on UK credit or financial institutions from establishing or continuing a correspondent banking relationship, and from processing sterling payments to, from or via a designated person or a credit or financial institution owned or controlled by them.
- A prohibition on dealing with transferable securities and money market instruments issued on or after 1 March 2022 by the following:
For the purposes of these regulations, a person “connected with Russia” covers individuals or entities who are residents, incorporated, domiciled or otherwise located in Russia.
- The Russia (Sanctions) (EU Exit) (Amendment) (No. 3) Regulations 2022 (1 March 2022) amend the 2019 Regulations to impose several new trade restrictions on Russia via the following:
- Replacing the existing prohibitions relating to dual-use items with new prohibitions on the export, supply and delivery, making available and transfer of dual-use items to, or for use in, Russia, irrespective of end-user; and
- Prohibiting the export, supply and delivery, making available and transfer of critical industry items (including certain electronics, telecommunications equipment, and aerospace related items) to, or for use in, Russia (as well as related technical assistance, financial services, funds and brokering services).
- The Russia (Sanctions) (EU Exit) (Amendment) (No. 4) Regulations 2022 (3 pm on 1 March 2022) introduce new shipping sanctions measures, prohibiting banned UK ports from providing access to any ship which they have reason to believe is:
- Owned, controlled, chartered or operated by any person connected with Russia;
- Owned, controlled, chartered or operated by designated persons;
- Flying the Russian flag; or
- Registered in Russia.
- The Russia (Sanctions) (EU Exit) (Amendment) (No. 5) Regulations 2022 (5 pm on 1 March 2022) introduce a new prohibition against the provision of financial services for the purpose of foreign exchange reserve and asset management to the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, the Ministry of Finance of the Russian Federation, and any person owned and controlled directly or indirectly by, or a person acting on behalf of or at the direction of, the aforementioned.
OFSI GENERAL LICENSES
The UK Office of Financial Sanctions Implementation (OFSI), which is responsible for implementing and enforcing financial sanctions in the United Kingdom, published a number of General Licenses authorising certain acts (subject to specific conditions) which would otherwise be prohibited under the 2019 Regulations (as amended) to allow for persons affected to arrange their affairs and comply with the new restrictions. These include:
- General licence -INT/2022/1277777, authorising certain dealings of transferable securities or money market instruments until 8 March 2022;
- General licence -INT/2022/1277778, authorising UK credit and financial institutions to have correspondent banking relationships with Sberbank and its connected entities, and to process certain Sterling payments made by Sberbank and its connected entities until 31 March 2022;
- General licence – INT/2022/1277877, authorising UK credit and financial institutions to process Sterling payments with Sberbank and its connected entities for the purposes of making “relevant energy products” (such as oil, gas and petroleum products) available for use in the United Kingdom until 24 June 2022; and
- General licence – INT/2022/1272278, authorising winding down transactions involving VTB Bank, VTB Capital plc and its UK subsidiaries until 27 March 2022.
UK TARGETED SANCTIONS
Since the start of Russia’s military activity in Ukraine, the United Kingdom has been regularly updating its list of individuals and persons subject to travel bans and asset freezes. Targeted entities include major Russian banks (such as VTB Bank, Sberbank and SovComBank), companies in key Russian sectors (such as United Aircraft Corporation and Rostec) and key Russian individuals (such as Denis Alexandrovich Bortnikov, Deputy President and Chairman of VTB Bank’s Management Board, and Elena Alexandrovna Georgieva, Chairwoman of Novikombank). The full list of designated persons is available on The UK Sanctions List.
UK asset freezes apply to funds and economic resources owned, held or controlled by a sanctioned person as well as entities owned or controlled directly or indirectly by sanctioned persons. A non-sanctioned entity will be considered as being owned or controlled by a sanctioned person if: (i) the sanctioned person holds more than 50% of the shares or voting rights in the entity or has the right to appoint or remove a majority of the board of directors of the entity; and/or (ii) it is reasonable to expect that affairs of the entity are conducted in accordance with the sanctioned person’s wishes.
IMPACT FOR BUSINESSES
As the scope and variety of UK sanctions against Russia continues to increase, businesses will need to take swift action to limit their exposure.
- If you or your company have business relationships with Russian entities, consider whether it is feasible continue such relationships, and if not, review relevant contractual agreements and take steps to terminate such relationships;
- If you or your business have a bank account with a subsidiary of a Russian sanctioned bank (either in the European Union or United Kingdom), consider whether you are covered by an OFSI General Licence to transfer funds out of the accounts;
- Implement robust sanctions screening provisions and monitor new developments; and
- Seek legal advice if you are concerned about potential exposure.
***
HOW WE CAN HELP
If you have assets in Russia or business dealings with Russian entities or individuals (even if they are not listed as “designated persons”), or are concerned about the impact of new sanctions against Russia, please reach out to our lawyers for advice.
Raminta Dereskeviciute (London); Sabine Naugès (Paris); Alexa Ningelgen (Düsseldorf); David J. Levine (Washington, DC); Alan Kashdan (Washington, DC); Raymond Paretzky (Washington, DC)

CMS Announces Request for Applications for Participation in the ACO REACH Model
ARTICLE / CLIENT ALERT
CMS Announces Request for Applications for Participation in the ACO REACH Model
March 3, 2022
Read time: 16 min
On February 24, 2022, the Centers for Medicare and Medicaid Services (CMS) Innovation Center announced a Request for Applications (RFA) for the Accountable Care Organization (ACO) Realizing Equity, Access, and Community Health (REACH) model—a redesign of the Trump administration’s Global and Professional Direct Contracting (GPDC) model. The application portal will be available beginning March 7, 2022, and will close at 11:59 pm Eastern on April 22, 2022. Current Direct Contracting Entities (DCEs) will not be required to submit an application, and will be accepted into the ACO REACH model if they have a strong compliance record in the GPDC model and agree to comply with REACH model requirements.
This On the Subject covers some of the significant changes to the GPDC model reflected in the new ACO REACH model. A CMS summary of the model changes is available here.
Background on Direct Contracting
In 2019, the Trump administration announced three direct contracting models as part of its Primary Cares Initiative: the Geographic, Global and Professional models. The GPDC model built on the Innovation Center’s advanced ACO model portfolio, including the Pioneer and Next Gen ACO models. Some key differences from other Medicare ACO models included additional cash flow options, lower beneficiary thresholds that allowed entities with less experience with traditional Medicare populations to participate, and lower thresholds for provider participation in the DCE’s governance structure. GPDC used the same alignment methodologies—claims-based and voluntary alignment—as other Medicare ACO models. Beneficiaries in these models retained access to any Medicare provider and had all the rights and protections of traditional Medicare beneficiaries. Entities began participating in the GPDC model in an implementation period in October 2020; the first performance year (PY) began in April 2021. The Biden administration announced subsequently that it would not take additional applicants for the second cohort in 2022, but would allow deferred applicants and Next Generation ACOs to participate in the second performance year. A full list of 2021 and 2022 participants, nearly 100 entities, is available here.
The Trump administration also announced the direct contracting model options also included a Geographic track. This model incorporated new features, allowing any HIPAA-covered entity to participate, and would have included random alignment of beneficiaries in select geographic areas, in addition to claims-based and voluntary alignment. Although the Trump administration announced that it would launch the Geographic model in 2021, the Biden administration placed the model under review before any entities applied.
For a detailed explanation of the GPDC and Geographic models, see our previous analysis here.
Direct Contracting Controversy
The direct-contracting model portfolio faced increasing criticism on Capitol Hill, including a letter signed by 54 Democratic members of the House of Representatives and statements made at a hearing by Senator Elizabeth Warren (D-MA) calling for immediate termination of the model. Criticisms seemed to focus on the auto-alignment feature of the Geographic model, erroneous assertions that patients were subject to prior authorization and narrow networks, and allegations that the model represented the privatization of Medicare.
Over the past several weeks, advocates supporting the model launched a comprehensive campaign urging CMS to maintain the model with certain modifications. More than 200 provider organizations, including ACOs and DCEs, urged CMS to keep and improve GPDC. A group of 14 prior Obama administration officials likewise wrote in support of retaining and amending the model. Ultimately, CMS announced a combined approach, addressing some stakeholder concerns, while retaining model options for 2022 and beyond.
CMS Announces the Redesign of the Direct Contracting Portfolio
On February 24, 2022, CMS announced a redesign of the direct contracting model portfolio:
Cancelling Geographic Direct Contracting. CMS ultimately decided to officially cancel the Geographic Direct Contracting model. Although the model was never launched, the official cancellation is significant. As the Biden administration considers mechanisms to increase attribution among underserved populations, random or auto-alignment mechanisms could be one key policy tool used to align underserved beneficiaries who would not otherwise align through claims-based or voluntary alignment mechanisms because they do not have frequent interactions with the health system. Abandoning this mechanism now is a notable policy choice and something to watch for future model development, particularly because of the CMS goal of having every Medicare beneficiary and most Medicaid beneficiaries in an accountable care relationship by 2030.
Creating stability for DCEs for 2022. Despite calls for immediate termination, CMS retained the GPDC model for the remainder of 2022. This decision acknowledges the severe instability that would have been created had the Innovation Center terminated the model. DCEs can offer supplemental benefits and additional access to services funded through pre-payment options that would not otherwise be allowable under traditional Medicare, due to waivers and flexibilities that are available only under Innovation Center authorities. Premature termination of the model would have meant massive disruption to provider contracts and to Medicare benefits for seniors currently participating in these models. By extending the model for 2022, CMS created a smoother glidepath into the new ACO REACH in 2023.
Transitioning GPDC to ACO REACH in 2023. CMS also announced that it would address some of the key complaints about GPDC in ACO REACH, a redesign of the GPDC model. The ACO REACH model modifies the GPDC model according to three overarching goals: (1) advancing health equity to bring the benefits of accountable care to underserved communities; (2) promoting provider leadership and governance; and (3) protecting beneficiaries and the model through enhanced participant vetting, monitoring and transparency.
ACO REACH Model Overview
While some aspects of the ACO REACH model remain the same as in the GPDC model, CMS modified several key model design elements, including the ACO’s ownership and governance structure, health equity requirements and incentives, benefit enhancements, monitoring and compliance requirements, risk adjustment methodology, and other components of the financial methodology.
The model will run through four performance years, beginning on January 1, 2023, and ending on December 31, 2026. Like GPDC, accepted applicants will also have the option of participating in an implementation period in advance of the first performance year; for REACH, that will run from August 1 through December 31, 2022.
Participant Types
As in the GPDC model, the ACO REACH model has three categories of participation: Standard ACOs, New Entrant ACOs and High Needs Population ACOs. Selection into one of these categories is based on the organization’s level of experience with accountable care models and based on the population served:
- Standard ACOs have substantial experience serving traditional Medicare patients, including dual eligibles, who are aligned to an ACO through voluntary or claims-based alignment. Standard ACOs may have gained their experience through participation in Innovation Center shared savings models and/or in the Medicare Shared Savings Program (MSSP).
- New Entrant ACOs have not traditionally provided services to the traditional Medicare population and will primarily rely on voluntary alignment during the first few model performance years (although claims-based alignment will also be used).
- High Needs Population ACOs serve traditional Medicare patients with complex needs, including dual eligibles, who are aligned to an ACO through voluntary alignment or claims-based alignment. CMS expects that High Needs Population ACOs will implement a care model designed for beneficiaries with complex needs, such as the Programs of All-Inclusive Care for the Elderly (PACE).
New to ACO REACH, CMS is clarifying in the RFA that the model is intended only for applicants that serve a general, heterogenous population of fee-for-service (FFS) Medicare beneficiaries or sub-populations for which there is no existing targeted total cost of care initiative. As an example, the RFA states that organizations that serve primarily beneficiaries with chronic kidney disease or end-stage renal disease should not apply for ACO REACH and are instead encouraged to apply for Kidney Care Choices.
Risk-Sharing Options
Like the GPDC model, ACO REACH offers two risk-sharing options for participating ACOs. The Professional option is a lower-risk-sharing arrangement (50% of savings/losses) in which the ACO receives a Primary Care Capitation Payment, a risk-adjusted monthly payment for primary care services provided by the ACO’s participating providers. The Global option is a higher-risk-sharing arrangement (100% of savings/losses) with two available payment options. Global participants can elect to receive either a Primary Care Capitation Payment (as available under the Professional option) or a Total Care Capitation Payment, a risk-adjusted monthly payment for all covered services (including specialty care) provided by the ACO’s participating providers.
Advanced Alternative Payment Models Status
ACO REACH’s Global and Professional risk-sharing options currently both meet the criteria under 42 C.F.R. § 414.1415 to be Advanced Alternative Payment Models (Advanced APMs). CMS anticipates that both ACO REACH risk-sharing options will continue to meet the criteria for all subsequent performance years, subject to annual Advanced APM determinations. Eligible clinicians included on the REACH ACO’s Participation List (defined in 42 C.F.R. § 414.1305) will be eligible for Qualifying APM Participant (QP) determinations. However, ACOs and other Advanced APM participants should note that under current law, the advanced APM 5% bonus expires after the 2022 performance year/2024 payment year.
Key Changes from Direct Contracting and Implications
Governance
The RFA makes two notable changes to ACO governance beginning in PY2023. First, at least 75% of each ACO’s governing body must be held by Participant Providers or their designated representatives to ensure that participating ACOs operate as provider-led organizations. Previously, under the direct contracting model, Participant Providers were required to have only 25% control of the governing body. An ACO may request an exception to the 75% control requirement by submitting a proposal to CMS explaining how its governing body will otherwise involve Participant Providers in innovative ways. Any exception granted will be at the discretion of CMS.
By implementing this requirement, CMS is aligning ACO REACH with the provider governance thresholds set forth in MSSP and in the Next Gen ACO Model previously tested by the Innovation Center. The RFA indicates that the governing body must have “responsibility for oversight and strategic direction of the ACO and will be responsible for holding ACO management accountable for the ACO’s activities.” This includes the authority of the governing body to appoint and remove the chief executive of the ACO, but does not provide any other examples of specific rights that must reside with the ACO’s governing body rather than its parent company.
Second, the same individual may no longer fill both the Medicare beneficiary and consumer advocate roles on the ACO governing body, and CMS now further explicitly requires that each advocate must have voting rights. Consistent with the Innovation Center’s strategic goal to create patient-centered models, CMS emphasized in the RFA that it strongly encourages greater beneficiary participation in advising and informing ACO activities beyond the ACO governing body representation requirement. Where state law prohibits beneficiary representation on the governing body, the ACO must establish an alternative for ensuring that its procedures and policies adequately reflect beneficiary perspectives. Any alternative mechanism is subject to CMS approval.
Payment Model Changes
CMS made several key changes to the financial methodologies for ACO REACH Participants:
- Reduced the discount for the Global model. In the Direct Contracting model, CMS applied a discount to the performance-year benchmark that increased from 2% in 2021 to 5% over the duration of the model. In response to feedback from provider stakeholders, CMS reduced the discount in the ACO REACH model to range from 2% to 3.5% over the duration of the model.
| PY2021 | PY2022 | PY2023 | PY2024 | PY2025 | PY2026 | |
|---|---|---|---|---|---|---|
| Global DC | 2% | 2% | 3%* | 4%* | 5%* | 5%* |
| Global REACH | — | — | 3% | 3% | 3.5% | 3.5% |
* Note: As the ACO REACH model begins in PY2023, the DC model ceases to exist.
- Reduced quality withhold. In REACH, like Direct Contracting, the quality incentive will be structured as a withhold from the trended, regionally blended, risk-adjusted benchmark. The ACO then earns back some or all of the withheld amount depending on the ACO’s performance on quality measures and the ACO’s performance on continuous improvement/sustained exceptional performance (CI/SEP) criteria. The CI/SEP criteria under the REACH model will be detailed further in summer 2022. In the REACH model, the Innovation Center will reduce the quality withhold to 2% for PY2023 through PY2026, compared with a 5% quality withhold in Direct Contracting for those same years. The agency noted that this change was made in response to stakeholder feedback. Taken together, the reduced discount and reduced quality withhold should encourage greater provider participation in the model.
- Equity benchmarking adjustment. Beginning in PY2023, CMS will apply an adjustment to the benchmarks of ACOs depending on the proportion of underserved beneficiaries an ACO serves. CMS will identify underserved beneficiaries using a composite measure that incorporates a combination of Area Deprivation Index and Dual Medicaid Status. CMS will stratify aligned beneficiaries and identify the top decile for an upward adjustment of $30 per beneficiary per month (PBPM) and the bottom five deciles for a downward adjustment of $6 PBPM. Each REACH ACO will receive a net benchmark adjustment based on the number of aligned beneficiaries in each category. CMS indicates in the RFA that its modeling suggests that most ACOs will be marginally impacted by the adjustment, about +1% for those with the highest proportion of underserved beneficiaries and –0.5% for those with the lowest proportion of underserved beneficiaries. Initial reactions indicated that this benchmark approach could attract new types of model participants who had previously taken a pass on Direct Contracting.
- Risk adjustment. In Direct Contracting, two policies restrict growth in risk coding: (1) a coding intensity factor (CIF) limits risk score growth across the entire model; (2) a +/-3% symmetrical cap limits risk score growth over a two-year period. In ACO REACH, beginning in PY2024, CMS will modify the application of the risk score cap to (1) adopt a static reference-year population for the remainder of the model performance period; and (2) cap the REACH ACO’s risk score growth relative to the demographic risk score growth so that the +/-3% cap is appropriately adjusted based on demographic changes in the underlying population over time. We expect additional financial papers in summer 2022 that will detail the risk-adjustment changes and facilitate a deeper understanding of the proposed change.
New Benefit Enhancements
In addition to the benefit enhancements available for PY2021 and PY2022, CMS is proposing a new set of benefit enhancements that aim to leverage the relationships between beneficiaries and nurse practitioners, allowing ACOs to extend flexibilities under which NPs could undertake certain activities, including hospice care certification, certification of the need for diabetic shoes, certification of cardiac rehabilitation care plans, certification of plans of care for home infusion therapy, and referrals for medical nutrition therapy.
Additional Equity Information Collection
In alignment with the Biden administration’s goal of promoting health equity, the Innovation Center will require all REACH ACOs to develop and implement a Health Equity Plan, beginning in PY2023. REACH ACOs will submit annual Health Equity Plans in advance of each performance year for the duration of the model. The purpose of the Health Equity Plan is for ACOs to identify underserved communities within their aligned beneficiary populations and to implement initiatives to measure and reduce health disparities during the performance year. REACH ACOs must use template language provided by CMS—to be based on CMS’ Disparities Impact Statement—to develop their Health Equity Plan. The Health Equity Plan is a new requirement and additional guidance on content and implementation requirements will be forthcoming from CMS. REACH ACOs will also have additional reporting requirements related to the Health Equity Plan.
Considerations for Applicants
Screening and Disclosure Considerations for Investor-Backed Entities
As part of the screening process to determine eligibility for participation, CMS will conduct a program integrity review of the Applicant ACO or other relevant entities or individuals associated with the Applicant ACO. CMS notes that it may deny selection of an otherwise qualified Applicant ACO based on information found during the program integrity review. The review may include consideration of persons with an ownership or control interest in the Applicant ACO, key executives, equity partners (e.g., private equity or venture capital), and individuals or entities that the Applicant ACO expects will be Participant and Preferred Providers. Specifically, the Application Template requires Applicant ACOs to disclose each party with at least a 5% ownership interest in the Applicant ACO, as well as the ownership interests in the entities with an ownership interest in the Applicant ACO, including investment firms. Importantly, for purposes of the RFA, CMS defined “ownership interest” to mean the “[p]ossession of equity in the capital, the stock, or the profits of the subject entity.”
In addition, the Application Template further requires that if a privately held company that has an ownership or control interest in the Applicant ACO is a subsidiary of another privately held company, the Applicant ACO must list its parent company, or companies, and ownership interests in that privately held company. Applicant ACOs must disclose any relevant sanctions, corrective action plans, fraud investigations, outstanding debts owed to the Medicare program, criminal conduct and more that are related to these entities. As a result, investor-backed entities should carefully consider these requirements when completing the Application Template and structuring Applicant ACO ownership. From a policy perspective, CMS’s inclusion of these application requirements may be a recognition of the political interest, criticism and pressure exerted by some stakeholders in connection with requests to terminate or modify the Direct Contracting model.
Monitoring and Compliance Efforts
The RFA carries over many of the same monitoring and oversight requirements that were established under GPDC, including the requirement to have a compliance plan with certain attributes (e.g., designated compliance officer, compliance training) and CMS’s implementation of a monitoring plan that may include chart audits, a review of demographic data, interviews, site visits and more. In addition, CMS announced new monitoring and compliance efforts, including an annual assessment of whether beneficiaries are being shifted into or out of Medicare Advantage; an examination of an ACO’s risk score growth for the purpose of identifying inappropriate coding practices; increased use of data analytics to monitor service utilization; and a regular review of marketing materials to ensure that information being shared about the model is accurate, among other monitoring efforts.
Application Components and Timeline
CMS will evaluate Applicant ACOs based on the five domains included in the GPDC application, plus several additional domains. In the GPDC application, CMS evaluated applicants based on their (1) organizational structure, (2) leadership and management, (3) financial plan and risk-sharing experience, (4) patient centeredness and beneficiary engagement, and (5) clinical care. ACO REACH applicants will be evaluated within those domains and will also be evaluated on (1) whether they have a demonstrated, strong track record of “direct” patient care, (2) whether they have a demonstrated record of serving historically underserved communities with positive quality outcomes, and (3) whether their ownership structure imposes any “program integrity” risks.
Under current instructions, existing GPDC participants will not be required to re-apply to participate in the new model, but they will be required to sign new Participation Agreements and will be required to meet all ACO REACH requirements by January 1, 2023, to continue participation.
Conclusion
The ACO REACH model retains some of the core features of GPDC, including global payment options that made it attractive to providers interested in taking higher levels of financial risk and reward for their traditional Medicare patients. The new model responds to some critiques of the GPDC model by adjusting provider governance and the financial model, and by emphasizing health equity. Interested applicants should quickly evaluate the application materials and make a determination as to whether to apply, as the application requires in-depth disclosures and discussions of care management capabilities

Washington State Capital Gains Tax Held Unconstitutional
ARTICLE / CLIENT ALERT
Washington State Capital Gains Tax Held Unconstitutional
March 3, 2022
Read time: 4 min
The Washington State capital gains tax, which went into effect on January 1, 2022, has been held unconstitutional by the Douglas County Superior Court. Created in 2021, the tax was ostensibly labeled an “excise” tax in an effort by the Washington State Legislature (Legislature) to avoid difficulties associated with implementing an income tax in the state of Washington. The judge, however, was not persuaded.
Citing to authority from the Washington State Supreme Court, the trial judge held that courts must look through any labels the state has used to describe the statute and analyze the incidents of the tax to determine its true character. Here, the judge reviewed the most significant incidents of the new tax, including:
- It relies on federal income tax returns that Washington residents must file and is thus derived from a taxpayer’s annual federal income tax reporting;
- It levies a tax on the same long-term capital gains that the Internal Revenue Service (IRS) characterizes as “income” under federal law;
- It is levied annually (like an income tax), not at the time of each transaction (like an excise tax);
- It is levied on an individual’s net capital gain (like an income tax), not on the gross value of the property sold in a transaction (like an excise tax);
- Like an income tax, it is based on an aggregate calculation of an individual’s capital gains over the course of a year from all sources, taking into consideration various deductions and exclusions, to arrive at a single annual taxable dollar figure;
- Like an income tax, it is levied on all long-term capital gains of an individual, regardless of whether those gains were earned within Washington and thus without concern of whether the state conferred any right or privilege to facilitate the underlying transfer that would entitle the state to charge an excise;
- Like an income tax and unlike an excise tax, the new tax statute includes a deduction for certain charitable donations the taxpayer has made during the tax year; and
- Unlike most excise taxes, if the legal owner of the asset who transfers title or ownership is not an individual, then the legal owner is not liable for the tax generated in connection with the transaction.
The court found that these incidents show the hallmarks of an income tax rather than an excise tax, and because the new capital gains tax did not meet the uniformity and limitation requirements of the Washington State Constitution, it was unconstitutional.
The Washington State Attorney General has already indicated that the ruling will be appealed; in all likelihood, this issue will ultimately be decided by the Washington State Supreme Court. In the meantime, if you have questions about the Washington State capital gains tax, please contact Troy Van Dongen.

Illinois Supreme Court Eliminates Defense to Biometric Privacy Class Actions
ARTICLE / CLIENT ALERT
Illinois Supreme Court Eliminates Defense to Biometric Privacy Class Actions
March 3, 2022
Read time: 4 min
Illinois’ Biometric Information Privacy Act (BIPA) has spawned a tsunami of class actions against employers who utilize biometric timekeeping or security systems. Now, the Illinois Supreme Court in McDonald v. Symphony Bronzeville Park, LLC has eliminated a defense invoked by employers facing claims under BIPA: the exclusivity of workers’ compensation.
BIPA protects Illinois residents’ biometric information—including fingerprints, voice prints, retina scans and face scans—by regulating its collection and disclosure by private entities. It has become popular for class actions because it provides liquidated damages for technical violations, including damages of $1,000 per negligent violation or $5,000 per reckless or intentional violation—even if there is no actual harm to an individual.
In contrast, Illinois’ Workers Compensation Act (IWCA) provides damages according to a set fee schedule, in administrative proceedings but without class actions. Thus, until McDonald, employers could argue that alleged work-related privacy violations under BIPA were work-related injuries, and so preempted by IWCA.
In McDonald, both the trial and appellate courts rejected this preemption defense. The Illinois Supreme Court agreed, explaining that BIPA offers remedies for different types of injuries. IWCA only covers certain types of work-related injuries: those that are “psychological or physical.” BIPA, meanwhile, protects against injuries that are “personal and societal.”
WHAT SHOULD EMPLOYERS EXPECT AFTER MCDONALD?
- Resumption of stayed cases: The McDonald decision was not unexpected, but dozens of BIPA cases were paused in the lower courts pending the issuance of this decision. Those cases will now resume, and employer-defendants will have one less defense available to answer them.
- More pleading amendments: McDonald initially pled “mental anguish” as an injury to gain standing but removed it from her complaint when it became clear that she needed to de-emphasize her psychological injury to win. Although Justice Burke described this move as “gamesmanship,” the Court’s decision will likely reinforce this practice.
- Possible legislative reform: The McDonald decision invited the legislature to intervene, noting that if a “different balance” should be struck under BIPA, that is a question for the legislature. Currently, there are six BIPA amendments currently pending in the Illinois Legislature; two are bipartisan.
WHAT ABOUT OTHER BIPA DEFENSES?
The Illinois Supreme Court is expected to rule on other BIPA defenses in the coming months: limiting accrual and the statute of limitations. Each of those is even more significant now that McDonald has eliminated the workers’ compensation defense. Let’s preview each:
- Accrual: The Illinois Supreme Court has yet to define what constitutes a “collection” of biometric information. Do claims accrue each time a company collects biometric data or only from the first instance? This question is critical for calculating damages. The Court is expected to decide the issue this year in Cothron v. White Castle.
- Statute of limitations: Should it be the five-year limitation, which is the Illinois Code of Civil Procedure’s general default for civil actions, or the one-year limitation established by the Code for privacy-related suits? The Illinois Supreme Court has agreed to hear an appeal of Tims v. Black Horse Carriers (App. No. 1-20-0563), which held that different limitations periods apply to different sections of the act. Specifically, that decision applied a one-year limitations period to claims relating to unlawful sales or disclosures of biometric information, but a five-year limitations period to all other claims. Since most BIPA claims brought against employers concern failure to maintain certain written policies or to obtain consent, these would fall under the five-year statute of limitations under Tims.
- Labor law preemption: In late February 2022, an Illinois appellate panel preserved a BIPA defense for employers who are party to a collective bargaining agreement. In Walton v. Roosevelt University, answering a certified question, the panel held that federal labor law preempts BIPA privacy claims asserted by employees covered by a collective bargaining agreements. This, too, is a case in which the Illinois Supreme Court may now be asked to review.
Ironically, No Surprises Act Catches Providers and Facilities Off Guard
ARTICLE
Ironically, No Surprises Act Catches Providers and Facilities Off Guard
March 2, 2022
Read time: 1 min

FDA Issues Proposed Rule to Amend Medical Device Quality System Regulation
ARTICLE / CLIENT ALERT
FDA Issues Proposed Rule to Amend Medical Device Quality System Regulation
March 1, 2022
Read time: 12 min
The US Food and Drug Administration (FDA) published its Medical Devices; Quality System Regulation Amendments proposed rule to amend the medical device Quality System Regulation (QSR) on February 23, 2022. While FDA generally frames the proposal as an effort to incorporate International Organization for Standardization (ISO) 13485 (2016) by reference, the proposal includes several key changes that medical device manufacturers should consider for potential comment. These include requirements relating to risk management within quality management systems (QMS), clarification and revisions to certain defined terms, recordkeeping requirements, current good manufacturing practice (cGMP) requirements for combination products, and changes to FDA’s long-standing Quality System Inspection Technique (QSIT) procedures.
FDA is accepting comments on the proposed rule (Docket No. FDA-2021-N-0507) through May 24, 2022.
The proposed rule amends the QSR at 21 CFR Part 820 to align with ISO 13485. FDA’s approach is consistent with its ongoing efforts to modernize and harmonize its medical device regulations. In the proposed rule, FDA expresses its intention to remove redundant regulatory requirements as well as barriers to market entry and patient access through harmonization with ISO 13485. Currently, device manufacturers that operate in multiple jurisdictions must comply with FDA’s Part 820 in addition to other requirements, such as ISO 13485. The timing of this proposed rule closely follows the effective date of the EU Medical Device Regulation (MDR), Regulation EU 2017/745, which took effect on May 26, 2021, and also incorporates ISO 13485.
Regulatory authorities around the world recognize ISO 13485 as the QMS standard for medical devices. ISO is an international nongovernment organization made up of experts and membership of standard-setting bodies from around the world. ISO works to develop standards that help ensure product quality and regulatory compliance across jurisdictions. The first version of ISO 13485, published in 1996 as a voluntary consensus standard, has evolved to provide a framework for quality management throughout the design and development processes for medical devices. As ISO 13485 has evolved, it has become more closely aligned with FDA’s Part 820.
In FDA’s view, ISO 13485 is substantially similar to FDA’s current regulatory framework, and differences between the current regulatory requirements and ISO 13485 are consistent with the intent behind FDA’s regulation. To accomplish harmonization, the proposed rule would incorporate the QMS requirements of ISO 13485 by reference and make certain changes to key areas of FDA’s regulatory framework. If the proposed rule is adopted, the name of the regulation at Part 820 would be updated from QSR to the Quality Management System Regulation (QMSR).
Key Takeaways and Concepts
Robust Risk Management Procedures
Risk management has long been a key component and central focus of quality assurance. The current QSR expressly addresses risk management activities primarily in the context of the risk analysis associated with design validation. See 21 CFR § 820.30(g).
Although Part 820 contemplates that manufacturers should address risk in various processes, such as corrective and preventive actions (CAPAs), through the incorporation of ISO 13485, FDA clarifies its intent to expressly address risk management and risk-based decision-making throughout the lifecycle of device manufacturing. According to FDA, ISO 13485 integrates risk management to a greater degree than FDA’s current regulatory framework. In the agency’s view, risk management is an “essential systematic practice” to ensure that devices are safe and effective. Therefore, if the proposed rule is adopted, manufacturers will likely need to enhance risk management procedures in all aspects of their businesses to align with the QMSR. FDA believes that this risk management approach results in ISO 13485 having a more flexible approach to quality, suggesting that the agency does not intend to change its longstanding position that the QSR provides a flexible “umbrella” approach to cGMP. ISO 13485, like current Part 820, must apply to many different types of devices, and manufacturers must determine how to appropriately implement the QSR according to the current state-of-the-art manufacturing for a specific device.
The proposed rule also would update the concept of QMS. The current 21 CFR § 820.5 requires manufacturers to establish and maintain a QMS that meets the requirements of 21 CFR Part 820. The proposed rule would instead require manufacturers to develop a QMS that complies with ISO 13485, as modified by the proposed Part 820. The QMS also would have to be documented (e.g., by recording quantitative data so manufacturers could analyze performance of their processes and protocols).
One open question is whether cybersecurity is considered to be a component of the enhanced risk management procedures required under the proposal. The agency has taken the position that cybersecurity is an important consideration to ensure quality when manufacturing and using medical devices. While the agency has been active in this area and has released many resources on the topic, the proposed rule is silent as to whether a QMS must include procedures to address cybersecurity. Likewise, ISO 13485 does not expressly address cybersecurity, but it may contemplate cybersecurity as a component of its risk management and software validation procedures.
Clarification Concerning Terminology
FDA highlights specific points of clarification in the proposed rule that may have implications for current company policies and quality management processes.
Definitions
- Top management. The proposed rule would replace the term “management with executive responsibility,” defined in 21 CFR § 820.3(n), with the term “top management,” which is currently used in ISO 13485 and defined in “Quality Management Systems – Fundamentals and Vocabulary,” ISO 9000:2015. FDA proposes to use the ISO term “top management” while retaining the current definition set out in 21 CFR § 820.3(n) (i.e., “those senior employees of a manufacturer who have the authority to establish or make changes to the manufacturer’s quality policy and quality system.”) This change, along with the rationale set forth in the proposed rule, emphasizes that senior employees of a device manufacturer’s business (including C-Suite or personnel at the most senior levels of the organization) are responsible for compliance with quality requirements and should promote a “culture of quality” in every aspect of the business. The proposed rule notes that a “culture of quality meets regulatory requirements through a set of behaviors, attitudes, activities, and processes.” This point of clarification supports the idea that FDA will continue to carry forward its trend of relying on the Park Doctrine principles to hold high-level executives within a business responsible for violations.
- Product. The term “product” at 21 CFR § 820.3(r) would be modified to clarify that the definition encompasses services and, by extension, third parties that provide services related to the design, development and manufacture of medical devices. The extent to which QSR should apply to service providers and the degree of oversight or purchasing controls that FDA would expect for service providers is not clear.
- Customer. FDA proposes to include a definition for the term “customer” that encompasses “persons or organizations, including users, that could or do receive a product or a service that is intended for or required by this person or organization . . . .” The term would include individuals inside or outside of the organization as well as individuals or organizations at many levels of the supply chain, including component manufacturers, contract manufacturers and end users. FDA emphasizes its expectation that component manufacturers comply with the QSR to the extent applicable, and that finished device manufacturers ensure the integrity of components they receive. The proposed rule also acknowledges that “customers” may impose requirements that do not directly impact safety or effectiveness, and indicates that FDA does not intend to enforce QSR for such activities. FDA does not provide examples of customer requirements that would exceed the scope of FDA’s authority. Therefore, manufacturers may want to request clarification on this point.
Clarification Concerning Certain Concepts
FDA specifically clarifies three concepts from ISO 13485 to describe their application to FDA’s regulatory regime:
- Organization. ISO 13485 describes the term “organization” as the entity responsible for creating a QMS. FDA proposes that the term ‘‘organization,’’ as used in ISO 13485, includes a “manufacturer,” as the term is defined in proposed 21 CFR § 820.3. This proposed change emphasizes FDA’s long-established expectation that contract manufacturers or outsourced service providers that perform specific or discrete steps in the manufacturing process, such as relabeling, repackaging or specification development, are expected to create or maintain quality systems that apply to their activities and functions.
- Safety and performance. FDA clarifies that the term “safety and performance,” which is used in ISO 13485 to refer to a standard to measure medical devices, has the same meaning as FDA’s “safety and effectiveness” standard set out in section 520(f) of the Federal Food, Drug, and Cosmetic (FD&C) Act. Acknowledging that some may “disagree about how two standards compare, whether one is more stringent than the other,” the agency does not intend to take a position on the comparison. Instead, it offers this point for the purpose of clarification when interpreting requirements under ISO 13485.
- Validation of processes. Although ISO 13485 uses the term “validation of processes,” the term is not defined in the standard. FDA confirms that the term refers to “process validation,” as that term is currently defined in 21 CFR § 820.3(z)(1).
Certain QSR Requirements Are Retained
Despite the incorporation of ISO 13485, certain QSR requirements will be carried forward if the agency adopts the proposed rule, including the following:
- The scope and application of ISO 13485’s “Design and Development” provisions. The scope of the current 21 CFR § 820.30(a) will remain the same if the proposed rule is adopted. Therefore, ISO 13485, Clause 7.3 (Design and Development), will apply only to the manufacturers of certain Class I devices (i.e., those listed in 21 CFR § 820.30(a)) in addition to manufacturers of Class II and Class III devices.
- Labeling and packaging requirements. FDA will retain its current requirements at Part 820 that address labeling and packaging operations if the proposed rule is adopted. While Clause 7.5.1(e) of ISO 13485 requires that manufacturers implement procedures for labeling and packaging, it does not provide further guidance. FDA’s believes that its requirements (e.g., inspection of labeling by the manufacturer) establish safeguards to mitigate against device recalls related to labeling and packaging, and therefore should remain in the regulation.
Recordkeeping
FDA proposes additional record control requirements to ensure that records are established and maintained in a consistent and concise manner that demonstrates their validity and authenticity. FDA emphasizes that its focus is on the substance “and not the physicality of the record.” Proposals include the following:
- Implementing the signature and date requirements for records subject to the records control provisions in Clause 4.2.5 of ISO 13485, underscoring FDA’s continued focus on ensuring the validity and authenticity of signatures and dating of quality and manufacturing records, including electronic records
- Establishing requirements to ensure that the information required by 21 CFR Part 803 (Medical Device Reporting) is also documented and captured in complaints and servicing records
- Requiring firms to document in their records the Unique Device Identification (UDI) for each medical device or batch of medical devices in accordance with 21 CFR Part 830 (Unique Device Identification)
- Retaining clarification from the current 21 CFR § 820.180 concerning confidentiality and protection of records to emphasize that FDA will protect such records in accordance with the agency’s public information and disclosure regulations at 21 CFR Part 20.
The proposed rule also provides clarification concerning manufacturers’ obligations to make records available. ISO 13485, Clause 4.2.5, requires that records be “readily identifiable and retrievable,” which FDA considers to be substantially similar to current FDA requirements. FDA clarifies that records may be kept at a location separate from the inspected establishment as long as they are readily available (i.e., the records may be made available during the course of an inspection). Foreign manufacturers maintaining records at remote locations would be expected to produce records within two working days following a request.
Combination Products
FDA also proposes conforming amendments to 21 CFR Part 4, which codifies the cGMP requirements applicable to combination products and provides a streamlined option for combination product manufacturers to demonstrate compliance with cGMP. In general, under FDA’s provisions, single-entity and co-packaged combination products with device constituent parts may comply with the cGMP requirements of one of the applicable sets of standards (including the applicable provisions of Part 820), instead of demonstrating compliance with all cGMP requirements. The proposed amendments do not impact the cGMP requirements for combination products. Instead, the agency proposes conforming amendments to 21 CFR Part 4 clauses to the corresponding ISO 13485 references. FDA specifically requests comments on the proposed conforming amendments and whether further changes are necessary to ensure compliance with 21 CFR Part 4.
Impact on Inspection Procedures
The proposed rule would not impact FDA’s inspection authority under the FD&C Act. However, if the proposed rule is adopted, FDA intends to replace QSIT, which is the agency’s historical approach to inspection. FDA would replace QSIT with an inspection approach that is consistent with the requirements of the proposed Part 820. The agency describes an approach that would be similar to QSIT (e.g., it would involve information collection to support inspection observations, including Form FDA 483). However, it is unclear exactly how this new approach would differ from QSIT. FDA also notes that its inspection would not be a substitute for an ISO 13485 certification process where such certification is required, nor would those who hold an ISO 13485 certificate be exempt from FDA inspection. While the new approach to inspection remains unclear, FDA indicates that it will engage in training and education activities if the proposal is implemented.
Next Steps for Manufacturers
This proposed rule presents a revised framework to the medical device QSR that industry has long anticipated. The proposed effective date for the proposed rule (and any final rule based on this proposal) will be one year after the date of publication of the final rule in the Federal Register. Therefore, once final, there will not be much time to come into compliance prior to the effective date. As described herein, certain proposed changes likely will have a significant impact. Stakeholders should review the relevant changes and consider engaging throughout the rulemaking process to improve the proposal.
FDA’s Device Good Manufacturing Practice Advisory Committee (DGMPAC) reviews proposed regulations concerning good manufacturing practices. DGMPAC plans to meet on March 2, 2022, from 9:00 am to 6:00 pm EST to discuss and make recommendations on the cGMP requirements for medical devices under Part 820, “to align more closely with an international consensus standard for medical devices used by other regulatory authorities.” DGMPAC meetings are open to the public, and webcast links for the March 2 meeting are available here.
As noted, FDA is accepting both electronic and written comments to the proposed rule (Docket No. FDA-2021-N-0507), which are due by May 24, 2022.

2022 IP Outlook Report: The Developments Shaping European IP Law
ARTICLE / REPORT
2022 IP Outlook Report: The Developments Shaping European IP Law
March 1, 2022
Read time: 2 min
While European intellectual property (IP) regimes have slowly digested the Brexit shock, brand owners are vacillating between optimism and apprehension in 2022 as they navigate continuous developments in IP law. At the forefront is the prospect of greater patent law harmonization with the entry into force of the Unified Patent Court (UPC) and the European patent with unitary effect. En route to this unification, however, are some anticipated challenges.

State Law Privacy Video Series | Ad-Tech
ARTICLE / CLIENT ALERT / VIDEO
State Law Privacy Video Series | Ad-Tech
March 1, 2022
Read time: 2 min
California, Virginia and Colorado have new privacy laws coming into effect in 2023. But now is the time to start preparing your business or organization for compliance.
In this video series, we examine the different aspects of these laws and provide you the knowledge and tools you need for proper compliance.
In this video, Associate Austin Mooney talks about how the new privacy laws will extend consumer opt-out rights to the use of data for targeted advertising.

